Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2. (2021)
Attributed to:
AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1101/2021.01.03.21249159
PubMed Identifier: 33442711
Publication URI: http://europepmc.org/abstract/MED/33442711
Type: Journal Article/Review
Parent Publication: medRxiv : the preprint server for health sciences